Pawlik Timothy M, Poon Ronnie T, Abdalla Eddie K, Zorzi Daria, Ikai Iwao, Curley Steven A, Nagorney David M, Belghiti Jacques, Ng Irene Oi-Lin, Yamaoka Yoshio, Lauwers Gregory Y, Vauthey Jean-Nicolas
Department of Surgery, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Arch Surg. 2005 May;140(5):450-7; discussion 457-8. doi: 10.1001/archsurg.140.5.450.
A subset of patients with hepatocellular carcinoma (HCC) with a diameter of 10 cm or larger may benefit from hepatic resection.
Retrospective study of a multi-institutional database.
Five major hepatobiliary centers.
We identified 300 patients who underwent hepatic resection for HCC 10 cm or larger.
Clinical and pathologic data were collected, and prognostic factors were evaluated by univariate and multivariate analyses. Patient survival was stratified according to a clinical scoring system and pathologic T classification.
The perioperative mortality rate was 5%. At a median follow-up of 32 months, the median survival was 20.3 months, and the 5-year actuarial survival rate was 27%. Four clinical factors-alpha-fetoprotein of 1000 ng/mL or higher, multiple tumor nodules, the presence of major vascular invasion, and the presence of severe fibrosis-were significant predictors of poor survival (all P<.05). Patients were assigned a clinical score according to the following risk factors: 1, no factor; 2, one or two factors; or 3, three or four factors. On the basis of the clinical score, patients could be stratified into only 2 distinct prognostic groups: no factor (score of 1) vs 1 or more factors (score of 2 or 3) (P<.001). In contrast, when patients were stratified according to pathologic T classification, 3 distinct groups were identified: T1 vs T2 vs T3 and T4 combined (P<.001). Fifty-six percent of the patients with a clinical score of 2 and 20% of patients with a clinical score of 3 actually had T1 or T2 disease on pathologic examination.
Patients with large HCCs should be considered for liver resection as this treatment is associated with a 5-year survival rate exceeding 25%. Clinical predictors should not be used to exclude patients from surgical resection because these factors do not reliably predict outcome.
直径10厘米或更大的肝细胞癌(HCC)患者的一个亚组可能从肝切除术中获益。
对多机构数据库的回顾性研究。
五个主要的肝胆中心。
我们确定了300例接受直径10厘米或更大的HCC肝切除术的患者。
收集临床和病理数据,并通过单因素和多因素分析评估预后因素。根据临床评分系统和病理T分类对患者生存情况进行分层。
围手术期死亡率为5%。中位随访32个月时,中位生存期为20.3个月,5年实际生存率为27%。四个临床因素——甲胎蛋白1000 ng/mL或更高、多个肿瘤结节、存在主要血管侵犯以及存在严重纤维化——是生存不良的显著预测因素(均P<0.05)。根据以下危险因素为患者分配临床评分:1,无危险因素;2,一个或两个危险因素;或3,三个或四个危险因素。根据临床评分,患者只能分为2个不同的预后组:无危险因素(评分为1)与1个或更多危险因素(评分为2或3)(P<0.001)。相比之下,根据病理T分类对患者进行分层时,可确定3个不同的组:T1组与T2组与T3和T4合并组(P<0.001)。病理检查显示,临床评分为2的患者中有56%以及临床评分为3的患者中有20%实际上患有T1或T2期疾病。
对于大肝癌患者应考虑行肝切除术,因为这种治疗的5年生存率超过25%。不应使用临床预测因素来排除患者接受手术切除,因为这些因素不能可靠地预测预后。